ERBB2 and breast cancer: As revealed in Fig. 4, the rate of HR+/HER2– breast cancer subtype was 52.7% in patients with de novo metastatic breast cancer, which is lower than primary breast cancer, consistent with the breast cancer statistics and other data11,14.